ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit – Allarity Therapeutics (NASDAQ:ALLR)

Photo of author

By Ronald Tech






Examining Allarity Therapeutics Inc. Securities Fraud Lawsuit Impact on ALLR Investors

Unveiling the Securities Fraud Lawsuit Against Allarity Therapeutics

BENSALEM, Pa., Oct. 10, 2024 /PRNewswire/ — A recent announcement by the Law Offices of Howard G. Smith has opened up an opportunity for investors, particularly those with significant losses, to take the lead in a securities fraud class action lawsuit against Allarity Therapeutics, Inc. (Nasdaq: ALLR).

Class Period and Lead Plaintiff Deadline

Class Period: May 17, 2022 – July 19, 2024

Lead Plaintiff Deadline: November 12, 2024

During the specified Class Period, investors encountered alleged missteps by the Company. The lawsuit accuses Defendants of a failure to disclose vital information, including the overstating of regulatory prospects related to the Dovitinib NDA, involving inappropriate conduct by three former officers, leading to legal risks…

As a consequence, investors who wish to partake in this action do not need to act now. They have the choice to retain their legal representation or remain an observer in the class action proceeding. For further information or any inquiries regarding the pending lawsuit, individuals can reach out to Howard G. Smith, Esquire, at the Law Offices of Howard G. Smith, located at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, via phone at (215) 638-4847, or through email at howardsmith@howardsmithlaw.com. Alternatively, interested parties can visit the official website.

Implications and Counseling

Legal proceedings may vary by jurisdiction, so it is advised that individuals check to ensure compliance with local laws and ethics. For additional details:

  • Law Offices of Howard G. Smith
  • Howard G. Smith, Esquire
  • Phone: 215-638-4847
  • Email: howardsmith@howardsmithlaw.com
  • Website: www.howardsmithlaw.com
See also  HOPE Therapeutics Expands Ketamine Clinic Network - NRX Pharmaceuticals (NASDAQ:NRXP) The Growth of HOPE Therapeutics and NRX Pharmaceuticals

This development throws a spotlight on the complexities and potential pitfalls that can befall investors in the realm of securities. Such lawsuits serve as a reminder of the importance of due diligence and oversight in the investing arena.

To access the original press release, please click here.

SOURCE Law Offices of Howard G. Smith

Market News and Data brought to you by Benzinga APIs